Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study (Q33404434)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michiel Thomeer

12

object named as

M Thomeer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

M Kreuter

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Vansteenkiste

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J R Fischer

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

W Eberhardt

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

H Zabeck

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Kollmeier

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Serke

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N Frickhofen

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Reck

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

W Engel-Riedel

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Neumann

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Schumann

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

P De Leyn

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

T Graeter

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Stamatis

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

I Zuna

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

F Griesinger

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Thomas

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

TREAT investigators

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

15 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

986-992

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Long-term complications of chemotherapy for germ cell tumours

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Long-term sequelae after cancer therapy--survivorship after treatment for testicular cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Noncancer causes of death in survivors of testicular cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: Subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS578

21 January 2018

Identifiers

10.1093/ANNONC/MDS578

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33404434&oldid=1950249364"